Fragment‐Based Screening of Heterocyclic Electrophiles Identified Acrylamide Bioisoteres for Covalent KRasG12C Inhibitors
Nikolett Péczka, Aaron Keeley, Péter Ábrányi‐Balogh, Zoltán Orgován, László Petri, Emma K. Grant, Chad Quinn, Soma Csanády, Ivan Randelovic, József Tóvári, Jacob Bush, György M. Keserű · 2026
Read Fragment‐Based Screening of Heterocyclic Electrophiles Identified Acrylamide Bioisoteres for Covalent KRasG12C Inhibitors by Nikolett Péczka, Aaron Keeley, Péter Ábrányi‐Balogh, Zoltán Orgován, László Petri, Emma K. Grant, Chad Quinn, Soma Csanády, Ivan Randelovic, József Tóvári, Jacob Bush, György M. Keserű (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13594984.txt.
Description
Nikolett Péczka and co-authors screened small chemical fragments for a cancer drug target in two thousand twenty-six. The target is a changed form of KRas, a protein that drives many cancers. Drugs that bind it permanently, through a cysteine site, are a promising route.
Their library held small ring-shaped fragments that can react with cysteine. Tests tracked which fragments labeled the target and how reactive they were. The best fragment was merged in computer models with a known drug core, then made and tested. It bound the target and slowed its activity in cancer cells. The authors say such screens can supply starting points for covalent drugs.
Catalog record
| CREATOR | Nikolett Péczka, Aaron Keeley, Péter Ábrányi‐Balogh, Zoltán Orgován, László Petri, Emma K. Grant, Chad Quinn, Soma Csanády, Ivan Randelovic, József Tóvári, Jacob Bush, György M. Keserű |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 38 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |